NanoViricides Holds 2024 Annual Meeting; Shareholder Proposals Approved ENDOTITLENanoViricides, Inc. recently convened its 2024 Annual Meeting of Stockholders on December 7, 2024. At the meeting, a substantial portion of the company’s voting stock wa

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NanoViricides’s 8K filing here.

NanoViricides Company Profile

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.